

SNYDER CAPITAL MANAGEMENT INC
Form SC 13G/A
February 13, 2009

SEC Page 1 of 6

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0145
Expires: December 31,
2009

Estimated average burden
hours per response 10.4

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No. 1)**

West Pharmaceutical Services, Inc.

—
(Name of Issuer)

Common Stock

—
(Title of Class of Securities)

955306105

—
(CUSIP Number)

December 31, 2008

—
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. **955306105**

—
1. Names of Reporting Persons.

Snyder Capital Management, Inc.

—
2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) _____

(b) _____

—
3. SEC Use Only _____

—
4. Citizenship or Place of Organization **Delaware**

Number of	5. Sole Voting Power	-0-
Shares	6. Shared Voting Power	1,487,882
Beneficially	7. Sole Dispositive Power	-0-
Owned by	8. Shared Dispositive Power	1,654,582
Each Reporting Person With:		

9. Aggregate Amount Beneficially Owned by Each Reporting Person **1,654,582**

—
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) _____

—
11. Percent of Class Represented by Amount in Row (9) **5.1%**

—
12. Type of Reporting Person (See Instructions)

—
CO

CUSIP No. **955306105**

Item 1.

(a) Name of Issuer

West Pharmaceutical Services, Inc.

(b) Address of Issuer's Principal Executive Offices

101 Gordon Drive, P.O. Box 645, Lionville, PA 19341-0645

Item 2.

(a) The names of the persons filing this statement are:

Snyder Capital Management, L.P. ("SCMLP") and Snyder Capital Management, Inc. ("SCMI") (collectively, the "Filers").

The direct parent company of SCMI is Natixis Global Asset Management, L.P. (formerly known as IXIS Asset Management North America, L.P.). Natixis Global Asset Management, L.P. is ultimately owned approximately 70 percent by Caisse Nationale des Caisses d'Epargne ("CNCE"), and Banque Federale des Banques Populaires ("BFBP") and 30 percent by the public (via a listing on the Euronext exchange in Paris).

SCMI and Natixis Global Asset Management, L.P. operate under an understanding that all investment and voting decisions regarding managed accounts are to be made by SCMI and SCMLP and not by Natixis Global Asset Management, L.P. or any entity controlling it. Accordingly, SCMI and SCMLP do not consider Natixis Global Asset Management, L.P. or any entity controlling it to have any direct or indirect control over the securities held in managed accounts.

(b) The principal business office of the Filers is located at:

One Market Plaza, Steuart Tower, Suite 1200, San Francisco, CA 94105

(c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

(d) This statement relates to shares of common stock of the Issuer (the "Stock").

(e) The CUSIP number of the Issuer is: **955306105**

CUSIP No. **955306105**

Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) (as to SCMLP).
- (f) An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
- (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) (as to SCMI).
- (h) A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) Group, in accordance with section 240.13d-1(b)(1)(ii)(J) (as to both Filers).

Item 4. Ownership.

See Items 5-9 and 11 of the cover page for each Filer.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

To the best of SCMLP's knowledge, no individual client's holdings of the Stock are more than five percent of the outstanding Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

SCMLP is a registered investment adviser. SCMI is the general partner of SCMLP.

CUSIP No. **955306105**

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2009

SNYDER CAPITAL MANAGEMENT, L.P.

By: Snyder Capital Management, Inc.
General Partner

By: Sonja Commer
Chief Compliance Officer
SNYDER CAPITAL MANAGEMENT, INC.

By: Sonja Commer
Chief Compliance Officer

Q:\EDGAR EasePlus\3321.002 Snyder\West Pharmaceutical 13G\west_pharmaceutical.rtf